Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women

被引:1
作者
Noriyuki, Maiko [1 ]
Sumi, Toshiyuki [1 ]
Zhi, Xu [1 ]
Misugi, Fumiko [1 ]
Nobeyama, Hiroyuki [1 ]
Yoshida, Hiroyuki [1 ]
Matsumoto, Yoshinari [1 ]
Yasui, Tomoyo [1 ]
Honda, Ken-Ichi [1 ]
Ishiko, Osamu [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Obstet & Gynecol, Abeno Ku, Osaka 5458585, Japan
关键词
cyclooxygenase-2; matrix metalloproteinases; uterine cervical cancer; vascular endothelial growth factor;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent changes in the lifestyle of young women have led to an increase in the rate of uterine cervical cancer. We investigated the clinicopathological characteristics of uterine cervical cancer in young women, and examined the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2). Tumor samples from 439 patients with uterine cervical cancer, who were initially treated at Osaka City University Medical School Hospital, Japan between 1995 and 2004, were stained immunohistochemically. The patients were classified into two groups according to age at onset: group Y included women aged <= 35 years, and group O included women aged >= 36 years. Group Y had more cases of squamous cell carcinoma, while group O had more advanced cases (P<0.05). Advanced cases (beyond stage Ib2) had a significantly worse prognosis in group Y than in group O (P<0.05). There were no differences between the two groups in the expressions of VEGF, MMP-2 and COX-2. However, in advanced cases (beyond stage Ib2), the expression of VEGF, MMP-2 and COX-2 was significantly greater in group Y than in group O (P<0.05). The above findings suggest that the expression of VEGF, MMPs and COX-2 is related to a worse prognosis for advanced uterine cervical cancer in young women.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 48 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]  
BROWN LF, 1993, CANCER RES, V53, P4727
[3]   Vascular endothelial growth factor and prognosis of cervical carcinoma [J].
Cheng, WF ;
Chen, CA ;
Lee, CN ;
Wei, LH ;
Hsieh, FJ ;
Hsieh, CY .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (05) :721-726
[4]  
CHUNG CK, 1981, GYNECOL ONCOL, V12, P348, DOI 10.1016/0090-8258(81)90135-9
[5]   High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma [J].
Davidson, B ;
Goldberg, I ;
Gotlieb, WH ;
Kopolovic, J ;
Ben-Baruch, G ;
Nesland, JM ;
Berner, A ;
Bryne, M ;
Reich, R .
CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (10) :799-808
[6]   PROSPECTIVE SURGICAL PATHOLOGICAL-STUDY OF DISEASE-FREE INTERVAL IN PATIENTS WITH STAGE IB SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
DELGADO, G ;
BUNDY, B ;
ZAINO, R ;
SEVIN, BU ;
CREASMAN, WT ;
MAJOR, F .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :352-357
[7]  
Elder DJE, 1997, CLIN CANCER RES, V3, P1679
[8]  
GAUTHIER P, 1985, OBSTET GYNECOL, V66, P569
[9]  
GILES D, 2003, CLIN CANCER RES, V9, P2651
[10]  
Gilles C, 1996, INT J CANCER, V65, P209